Worth reading
41Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
79.9
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPNet Sales766¥ millionYear on year +79.9%Progress 25.0%
Operating profit59¥ millionProgress 59.0%
Ordinary income63¥ millionProgress 57.3%
Net income attributable to owners of the parent52¥ millionProgress 52.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥1.29
Financial position at period-end
Total assets5,908¥ million
of which net assets 5,142 ¥ millionEquity ratio 87.0%vs. prior year-end -2.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueitems Segment Regenerative medicine products business / Net Sales 603,095 / Year on year against the same period last year 129.8, Segment Regenerative medicine contract services business / Net Sales 94,977 / Year on year against the same period last year -5.4, Segment Labsite business / Net Sales 68,772 / Year on year against the same period last year 8.3
Segment profititems Segment Regenerative medicine products business / Profit for the period 240,580 / Profit for the same period of the previous fiscal year -35,795 / Year on year against the same period last year Not disclosed, Segment Regenerative medicine contract services business / Profit for the period 45,431 / Profit for the same period of the previous fiscal year 50,673 / Year on year against the same period last year Not disclosed, Segment Labsite business / Profit for the period 14,471 / Profit for the same period of the previous fiscal year 18,304 / Year on year against the same period last year Not disclosed
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥3,070 million (YoY +40.6%)
Operating profit¥100 million
Ordinary income¥110 million
Net income¥100 million
Annual Dividend Forecast¥0 → ¥0（0.0%）
Factors Behind Changes in Business Performance
Revenue increased as a result of significantly higher sales in the regenerative medicine products business and steady growth in sales in the Labsite business.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Impairment lossNo applicable matters.
Depreciation and amortization¥33,665 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNone (対象者：Not disclosed)
Issued Shares at Period-End40,610,200 shares
Treasury Shares at Period-End250 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥766 million (YoY +79.9%) |
| Operating profit | ¥59 million |
| Ordinary income | ¥63 million |
| Profit attributable to owners of the parent | ¥52 million |
| Net income per share | ¥1.29 |
| Equity ratio | End of the current fiscal period 87 / End of previous period 89.6 |
| Total assets | ¥5,908 million |
| Net assets | ¥5,142 million |
| Full-year earnings forecast | Net Sales ¥3,070 million (YoY +40.6%) / Operating profit ¥100 million / Ordinary income ¥110 million / Net income ¥100 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | items Segment Regenerative medicine products business / Net Sales 603,095 / Year on year against the same period last year 129.8, Segment Regenerative medicine contract services business / Net Sales 94,977 / Year on year against the same period last year -5.4, Segment Labsite business / Net Sales 68,772 / Year on year against the same period last year 8.3 |
| Segment profit | items Segment Regenerative medicine products business / Profit for the period 240,580 / Profit for the same period of the previous fiscal year -35,795 / Year on year against the same period last year Not disclosed, Segment Regenerative medicine contract services business / Profit for the period 45,431 / Profit for the same period of the previous fiscal year 50,673 / Year on year against the same period last year Not disclosed, Segment Labsite business / Profit for the period 14,471 / Profit for the same period of the previous fiscal year 18,304 / Year on year against the same period last year Not disclosed |
| Depreciation and amortization | ¥33,665 thousand |
| Impairment loss | No applicable matters. |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 40,610,200 shares |
| Treasury Shares at Period-End | 250 shares |
| Factors Behind Changes in Business Performance | Revenue increased as a result of significantly higher sales in the regenerative medicine products business and steady growth in sales in the Labsite business. |
Items this document does not state (13)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogBreakdown of extraordinary income (loss)Changes in the scope of consolidationMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales in the regenerative medicine products business increased significantly, while sales in the Labsite business also grew steadily.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.